Time filter

Source Type

Urbana, IL, United States

Rockford University is a private American liberal arts college in Rockford, Illinois. It was founded in 1847 as Rockford Female Seminary and changed its name to Rockford College in 1892, and to Rockford University in 2013. The university is known as the alma mater of Nobel Peace Prize winner Jane Addams, who was a member of the class of 1881. Wikipedia.

Chey W.D.,University of Michigan | Drossman D.A.,University of North Carolina at Chapel Hill | Johanson J.F.,Rockford College | Scott C.,Sucampo Pharmaceuticals Inc. | And 2 more authors.
Alimentary Pharmacology and Therapeutics | Year: 2012

Background Irritable bowel syndrome with constipation (IBS-C) significantly decreases quality of life and the ability to perform daily living activities. Aim To demonstrate the long-term safety, tolerability and patient outcomes of lubiprostone in patients with IBS-C. Methods This extension study enrolled 522 IBS-C patients who had completed one of two randomised phase 3 studies. All enrolled patients received open-label lubiprostone orally for 36-weeks (8 mcg, twice daily). The primary objective was the assessment of long-term safety and tolerability, monitored via adverse events (AEs), laboratory parameters and vital signs. Additional outcome endpoints included monthly responder rates and patient evaluations of IBS-C symptom severity and impact on quality of life. Results The evaluable safety population comprised of 520 patients; 476 of which had patient reported outcome data available. The overall safety profile of lubiprostone during this study was similar to that observed in the preceding phase 3 studies. The most common AEs were diarrhoea (11.0%), nausea (11.0%), urinary tract infection (9.0%), sinusitis (9.0%) and abdominal distention (5.8%). Diarrhoea and nausea were the most common treatment-related AEs. No serious AEs were considered treatment-related. Seventeen patients discontinued due to a treatment-related AE, of which diarrhoea and nausea accounted for six (1.2%) and three (0.6%) respectively. For responder rates and patient-evaluated parameters (n = 476), all groups experienced significant improvements from baseline, with initial improvements maintained throughout the study. Conclusion In patients with irritable bowel syndrome with constipation, lubiprostone 8 mcg twice daily was found to be safe and well tolerated over 9-13 months of treatment. © 2012 Blackwell Publishing Ltd.

Dalstrom M.,Rockford College
Anthropology and Medicine | Year: 2013

International medical travel is a rapidly developing phenomenon that promises patients cheap and affordable medical care abroad. However, the logistics of making travel arrangements, selecting a medical provider, and evaluating quality can be a daunting task for even the most experienced traveler. At the nexus, connecting patients and providers are medical travel facilitators (MTFs), who are individuals and companies that market foreign medical care to patients. While the services that MTFs offer vary, they primarily focus on making foreign medical care more accessible to patients through commodifying the medical experience and providing logistical support. Although they are an important part of international medical travel they are often overlooked, especially along the US/Mexico border. This paper contributes to the discussion on medical travel by focusing on MTFs and the methods they employ through (1) discussing the characteristics and logistical challenges of medical travel; (2) identifying the different types of medical travel facilitators; and (3) addressing how MTFs remake patients into consumers. Findings suggest that while MTFs operate on a variety of different scales, and market their services differently, they all emphasize the consumer experience through advertising quality assurances and logistical support. © 2013 Taylor & Francis Group, LLC.

Negro R.,V. Fazzi Hospital | Stagnaro-Green A.,Rockford College
Endocrine Practice | Year: 2014

Objective: To evaluate the peer-reviewed literature on hypothyroidism, hyperthyroidism, and thyroid autoimmunity in pregnancy.Methods: We review published studies on thyroid autoimmunity and dysfunction in pregnancy, the impact of thyroid disease on pregnancy, and discuss implications for screening.Results: Overt hyperthyroidism and hypothyroidism are responsible for adverse obstetric and neonatal events. Several studies of association suggest that either subclinical hypothyroidism or thyroid autoimmunity increase the risk of complications. One randomized controlled trial showed that pregnant women with subclinical hypothyroidism benefit from treatment in terms of obstetric and neonatal complications, whereas another study demonstrated no benefit in the intelligence quotient of babies born to women with subclinical hypothyroidism. Thyroid autoimmunity has been associated with increased rate of pregnancy loss, recurrent miscarriage, and preterm delivery.Conclusion: Current guidelines agree that overt hyperthyroidism and hypothyroidism need to be promptly treated and that as potential benefits outweigh potential harm, subclinical hypothyroidism also requires substitutive treatment. The chance that women with thyroid autoimmunity may benefit from levothyroxine treatment to improve obstetric outcome is intriguing, but adequately powered randomized controlled trials are needed. The issue of universal thyroid screening at the beginning of pregnancy is still a matter of debate, and aggressive case-finding is supported. © 2014 AACE.

Negro R.,V. Fazzi Hospital | Stagnaro-Green A.,Rockford College
BMJ (Online) | Year: 2014

In prospective studies, the prevalence of undiagnosed subclinical hypothyroidism in pregnant women ranges from 3% to 15%. Subclinical hypothyroidism is associated with multiple adverse outcomes in the mother and fetus, including spontaneous abortion, pre-eclampsia, gestational hypertension, gestational diabetes, preterm delivery, and decreased IQ in the offspring. Only two prospective studies have evaluated the impact of levothyroxine therapy in pregnant women with subclinical hypothyroidism, and the results were mixed. Subclinical hypothyroidism is defined as raised thyrotropin combined with a normal serum free thyroxine level. The normal range of thyrotropin varies according to geographic region and ethnic background. In the absence of local normative data, the recommended upper limit of thyrotropin in the first trimester of pregnancy is 2.5 mlU/L, and 3.0 mlU/L in the second and third trimester. The thyroid gland needs to produce 50% more thyroid hormone during pregnancy to maintain a euthyroid state. Consequently, most women on levothyroxine therapy before pregnancy require an increase in dose when pregnant to maintain euthyroidism. Ongoing prospective trials that are evaluating the impact of levothyroxine therapy on adverse outcomes in the mother and fetus in women with subclinical hypothyroidism will provide crucial data on the role of thyroid hormone replacement in pregnancy.

Stagnaro-Green A.,Rockford College
Frontiers in Endocrinology | Year: 2015

During pregnancy, the thyroid gland must produce 50% more thyroid hormone to maintain the euthyroid state. Women with decreased thyroid reserve preconception, most typically due to Hashimoto's thyroiditis, may develop hypothyroidism during pregnancy. Data over the last 20 years have reported a strong association between subclinical hypothyroidism and adverse maternal/fetal events. As a result of this association, an increasing number of women are being screened for thyroid disease either preconception or at the first prenatal visit. Consequently, an ever increasing number of women are being initiated on levothyroxine for the first time during pregnancy. At present, there are very limited guidelines related to the management of the thyroid disease in these women postpartum. Based on an understanding of the physiology of the thyroid gland during pregnancy and postpartum, and the personal clinical experience of the author, recommendations for the postpartum management of women who were started on levothyroxine during pregnancy are presented. © 2015 Stagnaro-Green.

Discover hidden collaborations